Impact of obesity on allogeneic stem cell transplant patients: A matched case-controlled study
Impact of obesity on allogeneic stem cell transplant patients: A matched case-controlled study
复制标题
DOI：
10.1016/s0002-9343(96)00450-0
复制
发表时间：
1997-03-01
影响因子：
5.9
通讯作者：
Garrison, J
中科院分区：
文献类型：
--
作者：
Fleming, DR;Rayens, MK;Garrison, J
目得：确定肥胖对患有各种恶性肿瘤以及代谢紊乱的成人和儿童在高剂量治疗后接受异基因干细胞移植的存活率的影响。对来自同一机构的322例同种异体患者进行了匹配的病例对照评价，非肥胖和肥胖患者的中位随访时间分别为296天和120天，于1983年4月至1995年6月在肯塔基州大学进行。结果：非肥胖组和肥胖组的总生存率分别为35%和20%（P = 0.0045）。当患者按年龄分开时，成年患者保持这种差异，而儿童则没有。患者分层时;根据供体状态，组织相容性和非组织相容性成人在肥胖患者中的结果较差。然而，差异仅在组织相容性组中具有显著性（P = 0.0007）。死亡原因无显着分布在复发以及nonrecurrence mechanism.CONCLUSION：成人肥胖患者接受大剂量化疗与干细胞救援有更多的不良后果。复发和非复发的原因是肥胖和非肥胖组之间不同结果的原因。(C)1997年，Excerpta Medica，Inc.
PURPOSE: To determine the impact of obesity on survival after high-dose therapy followed by allogeneic stem cell transplant in adults and children with various malignancies as well as metabolic disorders.PATIENTS AND METHODS: A matched case-controlled evaluation of 322 allogeneic patients from a single institution with a median follow-up of 296 and 120 days among nonobese and obese patients, respectively, was conducted between April 1983 and June 1995 at the University of Kentucky. The overall survival distributions among subsets defined as either obese or nonobese were measured.RESULTS: The overall survival among the nonobese and obese was 35% and 20%, respectively (P = 0.0045). When patients were separated by age, the adult patients maintained this difference, while the children did not. When patients were stratified;according to donor status, both the histocompatible and the nonhistocompatible adults had an inferior outcome among obese patients. The difference, however, was significant only among the histocompatible group (P = 0.0007). Causes of deaths were insignificantly distributed among both relapse as well as nonrelapse mechanisms.CONCLUSION: Adult obese patients undergoing high-dose chemotherapy with stem cell rescue have a more adverse outcome. Both relapse and nonrelapse causes are responsible for the different outcome between obese and nonobese groups. (C) 1997 by Excerpta Medica, Inc.